Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/ 2a Pilot Trial of the Oral Hedgehog Signalling Inhibitor Glasdegib in Patients With Sclerotic Chronic Graft-Versus-Host Disease Refractory to Second-Line Treatment

NCT03415867 is registered in ClinicalTrials.gov with Grupo Espanol de trasplantes hematopoyeticos y terapia celular as lead sponsor.

NCT NCT03415867
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03415867 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/ 2a Pilot Trial of the Oral Hedgehog Signalling Inhibitor Glasdegib in Patients With Sclerotic Chronic Graft-Versus-Host Disease Refractory to Second-Line Treatment
Lead sponsor
Grupo Espanol de trasplantes hematopoyeticos y terapia celular
Phase
Phase 1/2
Overall status
Unknown status
Start date
January 9, 2018
Completion date
June 9, 2022
Enrollment
21 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

sclerodermoid chronic graft-versus-host disease (disorder)